Panmure Gordon reaffirmed their buy rating on shares of Hutchison China MediTech Limited (LON:HCM) in a report published on Friday morning. Panmure Gordon currently has a GBX 2,630 ($34.33) target price on the stock.

Separately, Beaufort Securities reissued a buy rating on shares of Hutchison China MediTech Limited in a report on Wednesday, August 3rd.

Shares of Hutchison China MediTech Limited (LON:HCM) opened at 1817.50 on Friday. The firm’s market capitalization is GBX 1.10 billion. The firm’s 50-day moving average price is GBX 1,837.09 and its 200-day moving average price is GBX 1,880.63. Hutchison China MediTech Limited has a one year low of GBX 1,612.50 and a one year high of GBX 2,896.60.

In related news, insider Nash,Christopher acquired 42 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was bought at an average cost of GBX 1,899 ($24.79) per share, with a total value of £797.58 ($1,041.09).

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.